118 related articles for article (PubMed ID: 6795758)
1. Beneficial effects of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death.
Lefer AM; Okamatsu S; Smith EF; Smith JB
Thromb Res; 1981 Aug; 23(3):265-73. PubMed ID: 6795758
[No Abstract] [Full Text] [Related]
2. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
Edmonds LC; Lefer AM
Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane synthetase inhibitors differentially antagonize thromboxane receptors in vascular smooth muscle.
Smith EF; Lefer AM; Smith JB; Nicolaou KC
Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(2):130-4. PubMed ID: 6276789
[TBL] [Abstract][Full Text] [Related]
4. Vascular smooth muscle thromboxane A2 receptors mediate arachidonic acid-induced sudden death in rabbits.
Pfister SL; Kotulock DA; Campbell WB
Hypertension; 1997 Jan; 29(1 Pt 2):303-9. PubMed ID: 9039119
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
6. Thromboxane synthetase inhibition as antithrombotic strategy.
Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
Lefer DJ; Mentley RK; Lefer AM
Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
[No Abstract] [Full Text] [Related]
9. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.
Randall MJ; Parry MJ; Hawkeswood E; Cross PE; Dickinson RP
Thromb Res; 1981 Jul 1-15; 23(1-2):145-62. PubMed ID: 6795753
[No Abstract] [Full Text] [Related]
10. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
11. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
12. The effects of aspirin and OKY-1581 on the metabolism of exogenous arachidonic acid in rat alveolar macrophages.
Punnonen K; Uotila P; Mäntylä E
Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):367-74. PubMed ID: 6431566
[TBL] [Abstract][Full Text] [Related]
13. Human blood platelet behaviour after inhibition of thromboxane synthetase.
Heptinstall S; Fox SC
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):31S-37S. PubMed ID: 6401998
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis.
Kadowitz PJ; Nandiwada PA; Spannhake EW; Rosenson RS; McNamara DB; Hyman AL
Chest; 1983 May; 83(5 Suppl):72S-74S. PubMed ID: 6404609
[No Abstract] [Full Text] [Related]
15. Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2 synthetase inhibitor.
Shibouta Y; Terashita Z; Inada Y; Nishikawa K
Eur J Pharmacol; 1985 Feb; 109(2):135-44. PubMed ID: 3922775
[TBL] [Abstract][Full Text] [Related]
16. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological mechanisms of sudden death induced by platelet activating factor.
Lefer AM; Müller HF; Smith JB
Br J Pharmacol; 1984 Sep; 83(1):125-30. PubMed ID: 6435705
[TBL] [Abstract][Full Text] [Related]
18. Role of thromboxanes and prostaglandin endoperoxides in the pathogenesis of eicosanoid induced sudden death.
Lefer AM; Burke SE; Smith JB
Thromb Res; 1983 Nov; 32(3):311-20. PubMed ID: 6419378
[TBL] [Abstract][Full Text] [Related]
19. Effects of selective inhibition of thromboxane synthesis on renal function in humans.
Zipser RD
Am J Physiol; 1985 Jun; 248(6 Pt 2):F753-6. PubMed ID: 3839111
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway.
Tobias LD; Hamilton JG
Adv Prostaglandin Thromboxane Res; 1980; 6():453-6. PubMed ID: 6770605
[No Abstract] [Full Text] [Related]
[Next] [New Search]
